Biogen seeks FDA approval for new investigational Alzheimer’s drug

SAN DIEGO (KUSI) – More than 5 million Americans are living with Alzheimer’s, and it is on the rise all over the country.

The pharmaceutical giant Biogen says it will ask the Food and Drug Administration for approval on its experimental Alzheimer’s medication to treat people with mild cognitive impairment and the earliest signs of Alzheimer’s disease.

Dan Sewell, Director of Senior Behavioral Health and a Professor of Psychiatry at UCSD, was in studio to discuss Biogen’s decision.

 

Categories: Health, In Studio Guests, Local San Diego News